US 12,109,179 B2
Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
Peter Virsik, Portola Valley, CA (US); Han-Jie Zhou, Foster City, CA (US); Marianne Dorothy Sadar, West Vancouver (CA); Raymond John Andersen, Vancouver (CA); Kunzhong Jian, Surrey (CA); and Daniel Andrew Golec, Vancouver (CA)
Assigned to ESSA PHARMA INC., Vancouver (CA); THE UNIVERSITY OF BRITISH COLUMBIA, Vancouver (CA); and PROVINCIAL HEALTH SERVICES AUTHORITY, Vancouver (CA)
Appl. No. 17/599,329
Filed by ESSA Pharma Inc., Vancouver (CA); The University of British Columbia, Vancouver (CA); and Provincial Health Services Authority, Vancouver (CA)
PCT Filed Mar. 27, 2020, PCT No. PCT/US2020/025545
§ 371(c)(1), (2) Date Sep. 28, 2021,
PCT Pub. No. WO2020/198712, PCT Pub. Date Oct. 1, 2020.
Claims priority of provisional application 62/857,519, filed on Jun. 5, 2019.
Claims priority of provisional application 62/842,980, filed on May 3, 2019.
Claims priority of provisional application 62/825,450, filed on Mar. 28, 2019.
Claims priority of provisional application 62/825,440, filed on Mar. 28, 2019.
Prior Publication US 2022/0218632 A1, Jul. 14, 2022
Int. Cl. A61K 31/145 (2006.01); A61K 31/203 (2006.01); A61K 31/519 (2006.01)
CPC A61K 31/145 (2013.01) [A61K 31/203 (2013.01); A61K 31/519 (2013.01)] 23 Claims
 
1. A method of treating cancer comprising administering to a subject in need thereof, a compound having the structure

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, and all-trans retinoic acid (ATRA).